NASDAQ:CRIS Curis (CRIS) Stock Price, News & Analysis $5.46 +0.47 (+9.42%) (As of 09/13/2024 08:53 PM ET) Add Compare Share Share Today's Range$5.00▼$5.4650-Day Range$4.18▼$6.9852-Week Range$3.80▼$17.49Volume28,200 shsAverage Volume37,442 shsMarket Capitalization$32.18 millionP/E RatioN/ADividend YieldN/APrice Target$26.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Curis alerts: Email Address Curis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside376.2% Upside$26.00 Price TargetShort InterestHealthy2.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.79) to ($4.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.59 out of 5 starsMedical Sector643rd out of 927 stocksBiological Products, Except Diagnostic Industry108th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingCuris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCuris has only been the subject of 1 research reports in the past 90 days.Read more about Curis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.45% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently increased by 113.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRIS. Previous Next 1.9 News and Social Media Coverage News SentimentCuris has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Curis this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CRIS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of Curis is held by insiders.Percentage Held by InstitutionsOnly 29.97% of the stock of Curis is held by institutions.Read more about Curis' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Curis are expected to grow in the coming year, from ($6.79) to ($4.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCuris has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Curis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Curis Stock (NASDAQ:CRIS)Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Read More CRIS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRIS Stock News HeadlinesSeptember 4, 2024 | prnewswire.comCuris to Present at Upcoming Healthcare Conferences in SeptemberAugust 23, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Curis (CRIS)September 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.August 7, 2024 | finance.yahoo.comAnalysts' Revenue Estimates For Curis, Inc. (NASDAQ:CRIS) Are Surging HigherAugust 5, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Curis (CRIS)August 5, 2024 | msn.comCuris, Inc. (NASDAQ:CRIS) Q2 2024 Earnings Call TranscriptAugust 4, 2024 | investing.comEarnings call: Curis reports advancements in cancer treatment studiesAugust 4, 2024 | finance.yahoo.comEarnings Update: Curis, Inc. (NASDAQ:CRIS) Just Reported And Analysts Are Boosting Their EstimatesSeptember 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.August 2, 2024 | markets.businessinsider.comBuy Rating on Curis’s Stock Amid Anticipated Data Updates and Promising Drug EfficacyAugust 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Curis on Strong Financials and Promising Emavusertib TrialsAugust 1, 2024 | seekingalpha.comCuris, Inc. (CRIS) Q2 2024 Earnings Call TranscriptAugust 1, 2024 | markets.businessinsider.comCuris Inc Q2 Loss Decreases, But Misses EstimatesAugust 1, 2024 | prnewswire.comCuris Provides Second Quarter 2024 Financial and Operating UpdateJuly 25, 2024 | money.usnews.comCuris IncJuly 25, 2024 | prnewswire.comCuris to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024July 10, 2024 | prnewswire.comCuris to Present at Upcoming Healthcare Conference in JulyJuly 8, 2024 | rttnews.comWill Curis' TakeAim Trials Hit The Mark? See More Headlines Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/16/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:CRIS CUSIP23126910 CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees60Year Founded2000Price Target and Rating Average Stock Price Target$26.00 High Stock Price Target$26.00 Low Stock Price Target$26.00 Potential Upside/Downside+376.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($8.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,410,000.00 Net Margins-468.18% Pretax Margin-468.18% Return on Equity-327.92% Return on Assets-68.03% Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual Sales$10.16 million Price / Sales3.17 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book1.63Miscellaneous Outstanding Shares5,894,000Free Float5,558,000Market Cap$32.18 million OptionableNo Data Beta3.33 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. James E. Dentzer (Age 57)President, CEO, Secretary, Treasurer & Director Comp: $1.07MMs. Diantha Duvall CPA (Age 52)M.B.A., CFO and Principal Financial & Accounting Officer Comp: $719.02kDr. Jonathan B. Zung Ph.D. (Age 58)Chief Development Officer Comp: $691.27kMr. Mark W. Noel (Age 65)Vice President of Technology Management & Intellectual Property Comp: $279.28kMs. Elif McDonaldVP of Investor Relations & Corporate CommunicationsDr. Reinhard Wilhelm von Roemeling M.D.Senior Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsCidara TherapeuticsNASDAQ:CDTXNeon TherapeuticsNASDAQ:NTGNX4 PharmaceuticalsNASDAQ:XFORAgenusNASDAQ:AGENVerastemNASDAQ:VSTMView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Bought 96,256 shares on 8/19/2024Ownership: 1.838%View All Institutional Transactions CRIS Stock Analysis - Frequently Asked Questions How have CRIS shares performed this year? Curis' stock was trading at $12.75 on January 1st, 2024. Since then, CRIS shares have decreased by 57.2% and is now trading at $5.46. View the best growth stocks for 2024 here. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.67) by $0.36. The biotechnology company had revenue of $2.55 million for the quarter, compared to analysts' expectations of $2.20 million. Curis had a negative trailing twelve-month return on equity of 327.92% and a negative net margin of 468.18%. When did Curis' stock split? Shares of Curis reverse split on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Curis' major shareholders? Top institutional shareholders of Curis include Point72 Asset Management L.P. (1.84%). View institutional ownership trends. How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV) and Amarin (AMRN). This page (NASDAQ:CRIS) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRIS Stock Alerts